Paratek is developing novel antibiotics based upon its expertise in tetracycline chemistry. The company was formed from a reverse merger with Nasdaq-listed Transcept Pharmaceuticals and Abingworth Partner, Michael Bigham, joined the combined company as Chairman and CEO (and remains Exec Chair). Paratek is a VIPE (Venture Investment in Private Equity). The company's lead product, NUZYRA® (omadacycline) is a once-daily intravenous and oral antibiotic for the treatment a new broad-spectrum antibiotic, is approved in the US for community-acquired bacterial pneumonia and for acute skin and skin structure infections. Its second approved product, SEYSARA®(sarecycline), is marketed by Almirall, LLC in the U.S. as a new once-daily oral therapy for the treatment of moderate to severe acne vulgaris. Paratek is listed on the NASDAQ with the ticker PRTK.